Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Role Preferences in Treatment Decisions Among Patients with Relapsing-remitting Multiple Sclerosis
Multiple Sclerosis
P1 - Poster Session 1 (8:00 AM-9:00 AM)
6-001
Patient involvement in therapeutic decisions improves satisfaction and adherence. However, limited information is available on how patients with RRMS face the decision-making process for disease-modifying treatments.

The aim of this study was to assess relapsing-remitting multiple sclerosis (RRMS) patients’ preferred role in making treatment decisions.

A multicenter, non-interventional study was conducted at 19 hospital-based MS care units in Spain. Adult patients with a diagnosis of RRMS (2017 revised McDonald criteria) and disease duration between 3 and 8 years were included. Patients´ preferred role in their closest treatment decision was measured using the Control Preference Scale (CPS). A battery of patient-reported and clinician-rated measures was administered. A multivariate logistic regression analysis was conducted.

A total of 198 patients were included. Mean age (SD) was 38.7 (8.5) years and 74.2% were female. Median disease duration (IQR) was 6.0 (4.0-7.0) years. Median EDSS score was 1.0 (0-2.0). Ninety-two patients (46.5%) adopted a collaborative attitude and preferred making the treatment decision jointly with the neurologist, 59 (29.8%) adopted a passive attitude and preferred the neurologist make the decision, and 47 (23.7%) showed active attitude preferring to make the decisions themselves. We found a higher perception of symptom severity (p=0.002), more fatigue (p=0.005), a lower physical quality of life (p<0.001), and a worse mental speed processing (p=0.002) among passive patients compared to active ones. The collaborative role was associated with age (OR=1.07, 95% CI 1.01, 1.13, p=0.010) in the multivariable analysis after adjustment for confounders. There was no association between patient’ role and disability, mood, anxiety, MS knowledge, risk-taking behavior, or self-management.

Although almost 50% of patients preferred a collaborative attitude in treatment decisions with their neurologists, one third preferred a passive approach. Adapting communication and participation strategies to the preferences of each RRMS patient may be crucial to improve the shared decision-making process.

Authors/Disclosures
Miguel Angel Hernandez Perez (Hospital Nuestra Senora de Candelaria)
PRESENTER
Miguel Angel Hernandez Perez has nothing to disclose.
Eva Fernandez-Diaz (Complejo Hospitalario Universitario de Albacete) No disclosure on file
Elisa Salas Alonso Elisa Salas Alonso has nothing to disclose.
Jesus Manuel Martin Martinez Jesus Manuel Martin Martinez has nothing to disclose.
Antonio Candeliere No disclosure on file
Francisco Barrero No disclosure on file
Ana M. Alonso Torres, MD Dr. Alonso Torres has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen. Dr. Alonso Torres has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Alonso Torres has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis.
Jose Luis Sanchez Menoyo, MD (Neurologia - Hospital Galdakao-Usansolo) Dr. Sanchez Menoyo has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Sanchez Menoyo has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Dr. Sanchez Menoyo has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Sanchez Menoyo has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Sanchez Menoyo has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis.
Laura Borrega Canelo No disclosure on file
Maria Rodriguez Rodriguez, MD (Neurologia - Hospital Lucus Augusti) Maria Rodriguez Rodriguez, MD has nothing to disclose.
Montserrat Gomez Gutierrez No disclosure on file
Sara Eichau Madueno Sara Eichau Madueno has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Sara Eichau Madueno has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Sara Eichau Madueno has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Sara Eichau Madueno has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Sara Eichau Madueno has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Sara Eichau Madueno has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Novartis. Sara Eichau Madueno has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Sara Eichau Madueno has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Sanofi. Sara Eichau Madueno has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Merck.
Carmen Calles, MD (Grupo 7 Viajes) Dr. Calles has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi, Biogen, Roche, Teva, Novartis, Merck. Dr. Calles has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi, Teva, Biogen, Roche, Novartis, Merck.
Olga Carmona No disclosure on file
Aida Orviz-García, MD (Fundacion Jimenez Diaz) Dr. Orviz-García has nothing to disclose.
Ana Lopez Real Ana Lopez Real has received personal compensation in the range of $0-$499 for serving as a Consultant for Roche. Ana Lopez Real has received personal compensation in the range of $0-$499 for serving as a Consultant for Sanofi Genzyme. Ana Lopez Real has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Genzyme. Ana Lopez Real has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck.
Pablo Lopez Munoz, MD (Neurologia - Hospital Arnau de Vilanova - Val) Pablo Lopez Munoz, MD has nothing to disclose.
Amelia Mendoza Rodriguez Amelia Mendoza Rodriguez has nothing to disclose.
Eduardo Aguera Morales, MD, PhD (As. ENINDE V14776132) Dr. Aguera Morales has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Aguera Morales has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis .
Jorge Maurino Jorge Maurino has received personal compensation for serving as an employee of Roche Pharma Spain, Medical Department.
Julia Sabin Munoz Julia Sabin Munoz has nothing to disclose.